Hepatobiliary Iminodiacetic Acid Scan and Magnetic Resonance Imaging Guided Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer

Inclusion Criteria

• Subjects must be >= 18 years of age at the time of signing informed consent
• Diagnosis of primary liver malignancy (including hepatocellular carcinoma [HCC] or cholangiocarcinoma) or liver metastasis from any primary solid tumor site by characteristic imaging findings on CT or MRI, clinical presentation, and/or pathologic confirmation of diagnosis; subjects with other current or prior malignancies are eligible for this study
• Patients with liver metastases must have at least one of the following clinical factors that may affect liver function: * History of liver resection (at any time) * History of cirrhosis (any cause), fatty liver disease, or hepatic insufficiency due to any cause * Prior radiation to the upper abdomen including radioembolization
• Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-2
• Subjects must have a Child-Turcotte-Pugh (CTP) score =< 7 to be eligible
• Patients who have been previously treated with non-SBRT liver directed therapies may be enrolled on study; at least 3 months must have elapsed between the most recent liver-directed therapy and study entry
• Ability to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
• Subjects with an allergy to contrast agents may be enrolled at the treating physician’s discretion with appropriate pre-treatment and symptom management

Exclusion Criteria

• Subjects who are pregnant or planning to become pregnant during the study; women of child bearing potential must have a negative pregnancy test
• Subjects must not have received chemotherapy within 2 weeks of planned first (1st) day of radiation therapy (RT)
• No more than 3 lesions may be treated; the maximum sum of the diameter(s) of the lesion(s) must be =< 6 cm
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (or infections requiring systemic antibiotic treatment), active upper gastrointestinal (GI) ulceration or hemorrhage, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would in the opinion of the investigator limit compliance with study requirements